SML2020
阿曲生坦 盐酸盐
≥98% (HPLC)
别名:
2R-（4-甲氧基苯基）-4S-（1,3-苯并二恶唑-5-基）-1-（N，N-二（正丁基）氨基羰基甲基）-吡咯烷-3R-羧酸盐酸盐, ABT-627盐酸盐, 盐酸A-147627, （2R，3R，4S）-4-（1,3-苯并二恶唑-5-基）-1- [2-（二丁基氨基）-2-氧乙基] -2-（4-甲氧基苯基）-3-吡咯烷羧酸盐酸盐
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C29H38N2O6 · HCl
CAS号:
分子量:
547.08
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77
推荐产品
![5-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[3,2-d][1,3]dioxol-6-yl 4-methylbenzenesulfonate AldrichCPR](/deepweb/assets/sigmaaldrich/product/structures/271/040/2c31c3ad-5d79-4a34-b334-e3ff6645d365/640/2c31c3ad-5d79-4a34-b334-e3ff6645d365.png)
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
2-8°C
SMILES字符串
[H]Cl.CCCCN(CCCC)C(CN1C[C@H](C2=CC=C(OCO3)C3=C2)[C@@H](C(O)=O)[C@@H]1C4=CC=C(OC)C=C4)=O
InChI
1S/C29H38N2O6.ClH/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20;/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34);1H/t23-,27-,28+;/m1./s1
InChI key
IJFUJIFSUKPWCZ-SQMFDTLJSA-N
一般描述
阿曲生坦也已用于治疗心血管疾病。
生化/生理作用
选择性内皮素 ETA 受体拮抗剂
阿曲生坦是一种选择性内皮素 ETA 受体拮抗剂，ETA 的 IC50 为 0.2 nM，而 ETB 受体的 IC50 为 190 nM。它阻断内皮素诱导的细胞增殖，已被研究作为前列腺癌的一种潜在疗法，最近又被用于糖尿病肾病的疗法。
储存分类代码
11 - Combustible Solids
WGK
WGK 3
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Determination of atrasentan by high performance liquid chromatography with fluorescence detection in human plasma.
Bryan P D, et al.
Biomedical Chromatography, 15(8), 525-533 (2001)
Carmen De Miguel et al.
Scientific reports, 7, 43152-43152 (2017-02-24)
Endothelin-1 (ET-1) promotes renal damage during cardiovascular disease; yet, the molecular mechanisms involved remain unknown. Endoplasmic reticulum (ER) stress, triggered by unfolded protein accumulation in the ER, contributes to apoptosis and organ injury. These studies aimed to determine whether the
Margien G S Boels et al.
Diabetes, 65(8), 2429-2439 (2016-05-22)
Atrasentan, a selective endothelin A receptor antagonist, has been shown to reduce albuminuria in type 2 diabetes. We previously showed that the structural integrity of a glomerular endothelial glycocalyx is required to prevent albuminuria. Therefore we tested the potential of
Chunhua Jin et al.
The Journal of pharmacology and experimental therapeutics, 351(2), 467-473 (2014-09-06)
Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门